Detalles de la búsqueda
1.
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
Cancer
; 130(10): 1747-1757, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38236702
2.
Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance).
Ann Surg Oncol
; 28(11): 5960-5971, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33821344
3.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 497-509, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29501363
4.
A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I.
Support Care Cancer
; 25(11): 3407-3416, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28551844
5.
Brief-exposure to preoperative bevacizumab reveals a TGF-ß signature predictive of response in HER2-negative breast cancers.
Int J Cancer
; 138(3): 747-57, 2016 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26284485
6.
Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).
Breast Cancer Res Treat
; 159(1): 109-18, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27449492
7.
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
Breast Cancer Res Treat
; 160(2): 297-304, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27704226
8.
Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
BMC Cancer
; 16: 274, 2016 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-27090210
9.
Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy.
Clin Obstet Gynecol
; 59(4): 756-771, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27741213
10.
Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Br J Haematol
; 169(3): 352-5, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25612847
11.
Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).
Ann Surg
; 262(3): 434-9; discussion 438-9, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26222764
12.
Assessing the role of platinum agents in aggressive breast cancers.
Curr Oncol Rep
; 17(2): 3, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25665554
13.
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.
BMC Cancer
; 14: 326, 2014 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24885187
14.
Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study.
Breast Cancer Res Treat
; 138(1): 215-23, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23354365
15.
Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response.
Chemotherapy
; 59(5): 387-94, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24852315
16.
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.
NPJ Precis Oncol
; 7(1): 18, 2023 Feb 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36797347
17.
Which patients with early-stage triple-negative breast cancer should receive a platinum?
Clin Adv Hematol Oncol
; 15(7): 510-514, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28749912
18.
Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis.
Breast Cancer (Dove Med Press)
; 14: 63-70, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35313558
19.
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.
NAR Cancer
; 4(2): zcac018, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35734391
20.
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
J Clin Oncol
; 40(12): 1323-1334, 2022 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35044810